Condition
Periportal Fibrosis
Total Trials
1
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
Treatment Research
4 treatments under study, led by Praziquantelantioxidant
Research Leaders
5 sponsors active, led by Ullevaal University Hospital
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 1 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
Not Applicable (1)
Trial Status
Unknown1
Clinical Trials (1)
Showing 1 of 1 trials
Showing all 1 trials
Research Network
Common Treatments
- Praziquantelantioxidant1
- Praziquantel Therapy And Placebo As Supplement1
- Praziquantel Placebo 2mths Then Antioxidant For 10 Mths1
- Praziquantelantioxidant Suppl1
Active Sponsors
- Ullevaal University Hospital1
- Addis Ababa University1
- University of Agder1
- University of Oslo1
- Sorlandet Hospital HF1
Top Investigators
Aklilu Lemma Institute of Pathobiology, Addis Ababa University
Ullevål University Hospital, Department of Infectious Diseases, Centre for Imported and Tropical Diseases, 0407 Oslo
Sorlandet Hospital HF, Box 416, 4604 Kristiansand - Norway
Institute for Basic Medical Sciences, Department of Nutrition, University of Oslo, P.O.box 1046, N-0316 Oslo, Norway
Related Conditions
- Liver Fibrosis1
- Oxidative Stress1
- Schistosomiasis1